GENFIT Share Price Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Sales 2024 * | 82.45M 88.31M 6.99B | Sales 2025 * | 48.61M 52.07M 4.12B | Capitalization | 173M 185M 14.64B |
---|---|---|---|---|---|
Net income 2024 * | 19M 20.35M 1.61B | Net income 2025 * | -21M -22.49M -1.78B | EV / Sales 2024 * | 1.99 x |
Net cash position 2024 * | 8.71M 9.33M 738M | Net cash position 2025 * | 44.9M 48.09M 3.81B | EV / Sales 2025 * | 2.63 x |
P/E ratio 2024 * |
13.6
x | P/E ratio 2025 * |
-36.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.86% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 30/04/18 |
Founder | 68 | 31/08/99 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 03/03/21 | |
Founder | 68 | 31/08/99 | |
Founder | 52 | 14/09/99 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |